{
    "abstract": "Adenomyosis is one of the structural causes of abnormal uterine bleeding, which often presents as heavy menstrual bleeding. Mostly because of the poor understanding of its pathophysiology, medical management of adenomyosis-induced heavy menstrual bleeding is still a challenge. We have previously reported that glycolysis is crucial to endometrial repair following menstruation and that suppressed glycolysis can cause heavy menstrual bleeding.\nThis study aimed to test the hypothesis that meclizine, a drug with an excellent safety profile, alleviates heavy menstrual bleeding in mice with induced adenomyosis using a simulated menstruation model.\nAdenomyosis was induced in 36 female C57BL/6 mice using endometrial-myometrial interface disruption. Three months after induction, the mice were randomly divided into the following 3 groups: low-dose meclizine, high-dose meclizine, and controls. Treatment with meclizine or vehicle started shortly before the simulated menstruation procedure and ended before progesterone withdrawal. The amount of blood loss was quantified and uterine tissue was harvested for histologic evaluation of the grade of endometrial repair. We performed immunohistochemistry analysis of 4 proteins critically involved in glycolysis: Glut1 (glucose transporter 1), Hk2 (hexokinase 2), Pfkfb3 (6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3), and Pkm2 (pyruvate kinase M2). The extent of tissue fibrosis in both ectopic and eutopic endometria was evaluated using Masson trichrome staining.\nIn mice with induced adenomyosis, meclizine accelerated endometrial repair in a dose-dependent manner and reduced the amount of menstrual bleeding. Meclizine administration raised endometrial immunoexpression of Hk2 and Pfkfb3 but not of Glut1 or Pkm2. The extent of endometrial fibrosis was reduced following the meclizine administration. Remarkably, these favorable changes were accompanied by the suppression of lesional progression, as evidenced by the dose-dependent reduction in the extent of fibrosis (a surrogate for lesional progression).\nThese encouraging results, taken together, suggest that glycolysis may be a promising therapeutic target and that meclizine may hold therapeutic potential as a nonhormonal treatment for adenomyosis-induced heavy menstrual bleeding without exacerbating the disease.",
    "authors": [
        {
            "affiliation": "Department of General Gynecology, Obstetrics & Gynecology Hospital, Fudan University, Shanghai, China.",
            "firstname": "Chenyu",
            "initials": "C",
            "lastname": "Mao"
        },
        {
            "affiliation": "Department of General Gynecology, Obstetrics & Gynecology Hospital, Fudan University, Shanghai, China.",
            "firstname": "Xishi",
            "initials": "X",
            "lastname": "Liu"
        },
        {
            "affiliation": "Shanghai Key Laboratory of Female Reproductive Endocrine-Related Diseases, Fudan University, Shanghai, China; Research Institute, Obstetrics & Gynecology Hospital, Fudan University, Shanghai, China. Electronic address: hoxa10@outlook.com.",
            "firstname": "Sun-Wei",
            "initials": "SW",
            "lastname": "Guo"
        }
    ],
    "conclusions": "These encouraging results, taken together, suggest that glycolysis may be a promising therapeutic target and that meclizine may hold therapeutic potential as a nonhormonal treatment for adenomyosis-induced heavy menstrual bleeding without exacerbating the disease.",
    "copyrights": "Copyright \u00a9 2024 Elsevier Inc. All rights reserved.",
    "doi": "10.1016/j.ajog.2024.02.016",
    "journal": "American journal of obstetrics and gynecology",
    "keywords": [
        "adenomyosis",
        "glycolysis",
        "heavy menstrual bleeding",
        "meclizine",
        "mouse model"
    ],
    "methods": null,
    "publication_date": "2024-02-18",
    "pubmed_id": "38367751",
    "results": "In mice with induced adenomyosis, meclizine accelerated endometrial repair in a dose-dependent manner and reduced the amount of menstrual bleeding. Meclizine administration raised endometrial immunoexpression of Hk2 and Pfkfb3 but not of Glut1 or Pkm2. The extent of endometrial fibrosis was reduced following the meclizine administration. Remarkably, these favorable changes were accompanied by the suppression of lesional progression, as evidenced by the dose-dependent reduction in the extent of fibrosis (a surrogate for lesional progression).",
    "title": "Meclizine improves endometrial repair and reduces simulated menstrual bleeding in mice with induced adenomyosis.",
    "xml": "<Element 'PubmedArticle' at 0x78850456dee0>"
}